Hanmi Pharma of Korea out-licensed global rights for three long-acting diabetes drugs to Sanofi in a blockbuster deal worth $4.2 billion; Sinocare, a Changsha glucose sensing device maker, will pay $273 million to acquire US-based Nipro Diagnostics, also in diabetes products; Roche will invest $136 million to build an Innovation Center in Shanghai; Bloomage BioTechnology, a China maker of aesthetic drug products, announced an $85 million investment from GIC of Singapore; ACEA Biosciences of San Diego and Hangzhou closed a $30 million venture capital round; Tianjin CanSino Biotech raised $30 million in venture capital to advance its vaccine programs; Tarrex Biopharma, a drug discovery startup based in Xiamen, purchased a 33% stake in Aranda Pharma of Finland and will co-develop its prostate cancer drug; iCarbonX of Shenzhen unveiled its big data/AI program to improve human health; Tsinghua University also announced a Medical Big Data Center at its Center for Statistical Science; JHL Biotech, a Taiwan-China biopharma, built a biologics CMO facility in Wuhan in just 11 days, using GE modular components; and Akers Biosciences of the US received CFDA approval of its diagnostic test for allergic reactions to heparin.
Help employers find you! Check out all the jobs and post your resume.
